T Cell Alloreactivity and Organ Transplant Risk Stratification Models Using High-Resolution HLA and Genomic Data
- Institution
- UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA
- Principal investigator
- Gerald Patrick Morris
- Funding
- $607K
- Duration
- 2025–2030
Moonbase score
Still being scored
Abstract
The conventional focus for histocompatibility in clinical solid organ transplantation focuses on humeral immunity, avoiding donor HLA molecules against which the recipient has pre-existing alloantibodies capable of mediating hyperacute rejection. While this is a practical approach mitigating some immunologic risk based on clinically available information, it does not address the inherent risks of T cell alloreactivity, which is a significant contributor to allograft rejection and requires life-long immunosuppression. In this proposal, we will leverage sequencing technologies and approaches adapted from immune-oncology to identify HLA allele-specific factors in solid organ transplant donors and recipients driving T cell alloimmune responses. We will develop a computational algorithm, CHART, to predict donor/recipient pair-specific T cell alloreactivity and risk of solid organ transplant rejection, with the goal toward precision medicine approaches for histocompatibility and personalized immunosuppression.
Research team
- Hannah Kathryn CarterPI
- Gerald Patrick MorrisPI
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF CALIFORNIA, SAN DIEGO
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of California, San DiegoNot yet scored
Development of novel model to measure TCR signal strength in dual TCR cells
Gerald Patrick Morris · $160K · 2025–2027
- NIH · University of California, San DiegoNot yet scored
Use of allogeneic pMHCII-based 5MCAR-CTLs to eliminate alloreactive lymphocytes in transplant
Michael S Kuhns · $228K · 2024–2026
- NIH · University of California, San Diego56
Defining the biological roles of the 2',3'-cyclic phosphatases Angel1 and Angel2
Megan Elizabeth Dowdle · $79K · 2024–2027